Close Menu

stock offering

The New Jersey-based cancer drug-discovery services provider said it had signed agreements to sell the shares to unnamed institutional investors.

A single healthcare-focused investor will purchase 2.78 million shares of common stock, 5.55 million prefunded warrants, and an additional 4.17 million shares of common stock.

Net proceeds from the offering will primarily support commercialization and further development of the company's DetermaRx and DetermaIO assays.

The firm will use the net proceeds for its planned $600 million acquisition of Decipher Biosciences, working capital, and other general corporate purposes.

The company said it has priced a public offering of 3,571,428 shares of its common stock at $70.00 per share.

The company will use the proceeds to commercialize and further develop its Proteograph Product Suite and for other R&D and corporate purposes.

The company is selling more than 3.9 million shares at $38 per share and has offered underwriters an option to add additional shares under the same terms.

The company said that it will use the proceeds to commercialize its Proteograph Product Suite but did not say when the offering will take place.

On Thursday, Predictive Oncology closed another direct offering initiated earlier in the week, raising $2.2 million.

The company plans to use the net proceeds for working capital, to improve its platform and tests, as well as to expand internationally and acquire assets. 


SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.